Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer

Next Previous
Trial Profile

A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 11 Sep 2024 According to an Ultimovacs media release, company announced that the company has agreed with the investigators conducting this trial to discontinue patient recruitment. The decision is driven by very slow recruitment in the study, which is primarily due to new treatment options available to NSCLC patients. All 31 patients that have been enrolled in the study since 2022 will be treated and followed up as per the trial protocol. Topline data from these patients expected in the first half of 2025.
  • 11 Sep 2024 Status changed from recruiting to active, no longer recruiting, according to an Ultimovacs media release.
  • 21 Aug 2024 According to an Ultimovacs ASA media release, as of date, 31 out of 138 patients have been enrolled in nine participating hospitals in Norway.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top